Poziotinib (formerly known as HM781-36B, NOV120101, HM781 36B) is a novel, potent, orally bioavailable, quinazoline-based, irreversible/co-valent pan-inhibitor of HER (human epidermal growth factor receptor 2) with potential antitumor activity.

AG-18 (also known as RG-50810, RG-50858, TX 825, Tyrphostin A23 and Tyrphostin AG-18) is a novel and potent EGFR inhibitor with an IC50 and Ki of 35 and 11 μM, respectively.

An antimicrobial peptide with angiogenic properties, AG-30/5C, activates human mast cells through the MAPK and NF-κB pathways.

Tyrphostin AG-528, formerly known as Tyrphostin B66, is a EGFR protein tyrosine kinase inhibitor.

EBE-A22 is a N-methyl derivative of PD-153035 which exhibits a very high affinity and selectivity for the epidermal growth factor receptor tyrosine kinase (EGF-R TK) and shows a remarkable cytotoxicity against several types of tumor cell lines.

AEE788 (NVP-AEE-788; NVP-AEE788) is a novel, potent and orally bioavailable inhibitor of multiple receptor tyrosine kinase such as EGFR (epidermal growth factor receptor) and HER2/ErbB2 with potential antitumor activity.

Gefitinib (formerly ZD1839, ZD-1839 or trade name: Iressa) is a potent and orally bioavailable EGFR inhibitor with potential anticancer activity.

Canertinib (formerly CI-1033; CI1033; PD183805; PD-183805) is an irreversible/covalent, quinazoline-based and orally bioavailable pan-ErbB inhibitor for EGFR and ErbB2 with potential antineoplastic activity.

Osimertinib (formerly AZD-9291 and mereletinib; trade name Tagrisso) is an oral bioavailable, irreversible/covalent, and mutant-selective EGFR inhibitor with potential antineoplastic activity.

AZ5104 (AZ-5104), a demethylated and active metabolite of Osimertinib (AZD-9291), is an irreversible EGFR inhibitor with potential antitumor activity.